Mereo BioPharma (MREO)

• Market cap: $47.3M
• 1 day: -3.14%
• 5 days: -12.6%
• 1 month: -11.42%
• 3 months: 23.46%
• 6 months: -23.63%
• Year to date: -41.95%
• 1 year: -81.25%
• 5 years: -89.42%
• 10 years: -95.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 39